9MER image
Entry Detail
PDB ID:
9MER
Title:
Structure of H1H5:FluA20 Chimeric Influenza HA Complex
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2024-12-08
Release Date:
2025-03-19
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.21
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 43 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:H1H5 HA
Chain IDs:A (auth: B)
Chain Length:227
Number of Molecules:1
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Description:FluA20 Heavy Chain Fab
Chain IDs:B (auth: H)
Chain Length:235
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FluA20 Light Chain Fab
Chain IDs:C (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structure-based Design of Chimeric Influenza Hemagglutinins to Elicit Cross-group Immunity.
Biorxiv ? ? ? (2025)
PMID: 40027756 DOI: 10.1101/2024.12.17.628867

Abstact

Antigenic variability among influenza virus strains poses a significant challenge to developing broadly protective, long-lasting vaccines. Current annual vaccines target specific strains, requiring accurate prediction for effective neutralization. Despite sequence diversity across phylogenetic groups, the hemagglutinin (HA) head domain's structure remains highly conserved. Utilizing this conservation, we designed cross-group chimeric HAs that combine antigenic surfaces from distant strains. By structure-guided transplantation of receptor-binding site (RBS) residues, we displayed an H3 RBS on an H1 HA scaffold. These chimeric immunogens elicit cross-group polyclonal responses capable of neutralizing both base and distal strains. Additionally, the chimeras integrate heterotrimeric immunogens, enhancing modular vaccine design. This approach enables the inclusion of diverse strain segments to generate broad polyclonal responses. In the future, such modular immunogens may serve as tools for evaluating immunodominance and refining immunization strategies, offering potential to bridge and enhance immune responses in individuals with pre-existing immunity. This strategy holds promise for advancing universal influenza vaccine development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures